Regulation network for regulating intracellular LRP6 expression level and plasma membrane transport and application thereof

The regulatory network of SDCCAG3 and VPS26 protein regulates LRP6 expression in Hela cells, solving the problems of osteoporosis and periimplant inflammation caused by hyperlipidemia, and improving bone density and the stability of implant dentures.

CN119019525APending Publication Date: 2024-11-26SHANDONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310585661.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-23
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Hyperlipidemia leads to osteoporosis and periimplant inflammation. The prior art is difficult to effectively regulate the LRP6 expression level and plasma membrane transport in cells, affecting bone metabolism and the stability of implanted dentures.

Method used

Through the regulatory network of SDCCAG3 protein and VPS26 protein, the expression level and plasma membrane transport of LRP6 in Hela cells are regulated, and its expression is promoted or inhibited to treat osteoporosis and periimplantitis.

Benefits of technology

By regulating the expression levels of SDCCAG3 and VPS26, significantly affecting the expression of LRP6 and plasma membrane transport, it provides a new way to treat osteoporosis and periimplantitis caused by hyperlipidemia, improving bone density and denture implantation stability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004243198730000011
    Figure HDA0004243198730000011
  • Figure HDA0004243198730000012
    Figure HDA0004243198730000012
  • Figure HDA0004243198730000021
    Figure HDA0004243198730000021
Patent Text Reader

Abstract

The invention relates to a regulation and control network for regulating and controlling the expression level of LRP6 and plasma membrane transport in cells and application of the regulation and control network. The mechanism that the expression level of LRP6 and plasma membrane transport in cells are regulated by the combined action of SDCAG3 protein and VPS26 protein is clarified from the protein level, and a regulatory network for regulating the expression level of LRP6 and plasma membrane transport in cells is provided, that is, the SDCAG3 protein and VPS26 protein jointly regulate the expression level of LRP6 and plasma membrane transport in Hela cells, and the expression level of LRP6 is influenced by SDCAG3 protein and VPS26 protein, so that the expression level of LRP6 is not influenced by SDCAG3 protein and VPS26 protein. In other words, the expression level of the LRP6 can also be reduced when the SDCAG3 protein or the VPS26 protein is knocked down in the Hela cell; according to the present invention, the expression level of the LRP6 protein can be increased when the SDCCAG3 protein or the VPS26 protein is over-expressed in the Hela cell, the over-expression of the SDCCAG3 protein and the VPS26 protein can inhibit the degradation of the LRP6 by the lysosome, and the knock-down of the SDCCAG3 protein or the VPS26 protein can promote the degradation of the LRP6 by the lysosome, such that the important significance is provided for the treatment of the diseases such as the osteoporosis and the peri-implantitis of the hyperlipidemia patient.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a regulatory network for regulating intracellular LRP6 expression level and plasma membrane transport and application thereof, belonging to the technical field of genetic engineering. Background Art

[0002] Hyperlipidemia is a metabolic disease mainly caused by a high-fat diet, characterized by abnormally elevated serum lipids. According to a large number of population surveys, the prevalence of hyperlipidemia in adults over 20 years old is approximately between 19.9% ​​and 33.5%. At the same time, the increased risk of diabetes, hypertension and cardiovascular diseases is positively correlated with the occurrence of hyperlipidemia. Hyperlipidemia can also induce atherosclerosis, which is a major risk factor for cardiovascular and cerebrovascular diseases. It may cause stroke, myocardial infarction and coronary heart disease. Hyperlipidemia is closely related to oral health. It has been confirmed that hyperlipidemia can damage the bone bonding of dental implants. Because with the improvement of people's living standards and the development of science and technology and materials science in the field of stomatology, implant dentures have become a conventional treatment strategy with a high success rate and a relatively good prognosis for the restoration of edentulous or missing teeth. The biological stability of the implant depends on good bone bonding, which is also the basis for determining the long-term success of implant dentures. However, although the methods of implant restoration are gradually simplified, and the safety and reliability are constantly improving, the prevalence of surrounding tissues is also increasing. Many epidemiological studies have found that increased blood lipid levels are positively correlated with the incidence of peri-implantitis, that is, increased total cholesterol levels in serum will increase the failure rate of implant restoration, because the homeostasis of bone metabolism mainly depends on the balance between osteogenesis and osteoclastogenesis. Studies have determined that patients with hyperlipidemia have increased adipogenesis and reduced osteogenesis in bone tissue; and hyperlipidemia will significantly damage bone metabolism, reduce bone density, bone strength and bone volume, and increase the risk of fractures and osteoporosis. Therefore, the bone density of patients with hyperlipidemia will decrease and the bone microstructure will be damaged, which will lead to poor initial stability after implant placement, reduced implant-bone interface strength and new bone formation, greatly increasing the failure rate of implant restoration.

[0003] Serologically defined colon cancer antigen-3 (SDCCAG3) is a protein with a molecular weight of 45 kDa. It has a coiled domain at its C-terminus, but has no obvious catalytic activity. When SDCCAG3 containing this coiled domain is overexpressed, it will lead to a decrease in the expression level of tumor necrosis factor receptor-1 (TNFR-1) and resistance to tumor necrosis factor-induced cell apoptosis, which indicates that SDCCAG3 may have some potential role in the intracellular transport of receptor molecules. In addition, SDCCAG3 also forms complexes with some other components that regulate membrane transport, such as ARF6 GTPase activating protein GIT-1 or vacuolar sorting protein-associated protein 35 (VPS35), one of the components of retromer. Therefore, SDCCAG3 may play a role in regulating the endocytic pathway of cargo transport or cargo sorting. At the same time, the localization of SDCCAG3 as a protein molecule in cells is also relatively complex. Studies have shown that SDCCAG3 is distributed at the base of the cell's primitive cilia and in the cytoplasm; the protein expression level of SDCCAG3 increases during the cell division period, and it can become part of the intermediate after the end of cell division; endogenous SDCCAG3 is located in early endosomes and recycling endosomes, which indicates that SDCCAG3 may be related to vesicle transport. Recent proteomic analysis has shown that SDCCAG3 interacts with Wiskott Aldrich syndrome protein and SCAR homolog (WASH) complex, forms a protein complex with the retromer Retromer, and regulates the endosomal transport of glucose transporter GLUT1 mediated by retromer molecules. Therefore, it can be found from the above that SDCCAG3 can mainly participate in processes such as cell division, vesicle transport and cell apoptosis.

[0004] Low Density Lipoprotein Receptor Related Protein 6 (LRP6) was identified as a member of the low-density lipoprotein (LDL) receptor family in 1998. The protein encoded by the human LRP6 gene contains 1613 amino acids, including a signal peptide and a transmembrane domain, and is highly conserved, a type I single-span membrane protein. Biochemical and genetic studies have found that members of the low-density lipoprotein receptor-related (LRP) family, especially LRP5 and LRP6 in vertebrates, are receptors of the typical Wnt signaling pathway, that is, an important link required for the activation of the Wnt / β-catenin signaling pathway. LRP6 can act as a co-receptor of the Wnt / β-catenin signal together with LRP5. After Wnt binds to its receptor Frizzled, LRP5 / 6 is recruited to form a complex with Wnt-Frizzled, ultimately promoting the stability of downstream β-catenin. LRP6 can be detected in different tissue types and is involved in many biological activities, such as cell proliferation, differentiation, migration, cancer metastasis, and embryonic development. LRP6 gene mutations are associated with premature hypercholesterolemia, atherosclerosis, and osteoporosis in humans. In addition, epidemiological studies have shown that osteoporosis is positively correlated with hyperlipidemia and secondary atherosclerosis, regardless of age. In particular, 63% of osteoporosis patients suffer from hyperlipidemia. People with high low-density lipoprotein levels are also more likely to suffer non-vertebral fractures. Aortic calcification is a recognized marker of atherosclerosis, positively correlated with the risk of osteoporosis and fractures, and low bone density is used as a clinical marker of atherosclerotic coronary artery disease. In addition, clinical studies and genomic analyses have confirmed that LRP6 gene variants accelerate the progression of hypertension, atherosclerosis, hypercholesterolemia, and other diseases. And mutations in LRP6 have been detected in osteoporotic syndrome, Alzheimer's disease, and diabetes.

[0005] Vacuolar sorting proteins 26 (VPS26) is a transport protein. VPS26, VPS29 and VPS35 are the three core proteins of the retromer complex, which assemble into a 1:1:1 150kDa heterotrimer. It is mainly involved in mediating the circulation of transmembrane proteins from endosomes to the Golgi apparatus. In mammals, VPS26 has two isoforms, VPS26A and VPS26B, which have overlapping functions but are not exactly the same. VPS26 is essential for mouse embryonic development and is downregulated in Alzheimer's disease, highlighting its importance in mammalian physiology. Vesicle transport is often studied using Drosophila as a conventional model. Literature studies have shown that in the larvae of Drosophila without VPS26, the autophagy and late endocytosis of fat cells are affected. The above research results have shown that VPS26 is indispensable for the growth and development of organisms and is closely related to the transport of intracellular substances. Summary of the invention

[0006] In view of the deficiencies in the prior art, the present invention provides a regulatory network for regulating the intracellular LRP6 expression level and plasma membrane transport and its application.

[0007] The technical solution of the present invention is as follows:

[0008] A regulatory network for regulating intracellular LRP6 expression level and plasma membrane transport, wherein the regulatory network is a SDCCAG3 protein-VPS26 protein regulatory network;

[0009] Among them, the Gene ID of the SDCCAG3 protein is: 10807; the Gene ID of the VPS26 protein is: 9559.

[0010] The present invention finds through research that in Hela cells, the expression of SDCCAG3 protein and VPS26 protein affects the expression level and plasma membrane transport of LRP6, wherein overexpression of SDCCAG3 protein or VPS26 protein promotes the expression of LRP6, and knockdown of SDCCAG3 protein or VPS26 protein inhibits the expression of LRP6; overexpression of both SDCCAG3 protein and VPS26 protein inhibits lysosomal degradation of LRP6, and knockdown of SDCCAG3 protein or VPS26 protein promotes lysosomal degradation of LRP6.

[0011] The application of the above regulatory network in the preparation of drugs for treating osteoporosis and peri-implantitis is characterized in that the application is the application of the regulatory factors of the above regulatory network in the preparation of drugs for treating osteoporosis and peri-implantitis.

[0012] Preferably according to the present invention, the regulatory factors of the regulatory network include but are not limited to: nucleic acid molecules, carbohydrates, lipids, polypeptides, proteins or lentiviruses.

[0013] Preferably according to the present invention, the drug regulates the expression level of LRP6 through SDCCAG3 and / or VPS26 protein, and the expression of LRP6 decreases when SDCCAG3 and / or VPS26 are knocked down, and the expression of LRP6 increases when SDCCAG3 and / or VPS26 are overexpressed.

[0014] Preferably according to the present invention, the osteoporosis is osteoporosis caused by or accompanied by hyperlipidemia; the peri-implantitis is peri-implantitis caused by or accompanied by hyperlipidemia.

[0015] Preferably according to the present invention, the drug contains an effective dose of the regulatory factor of the above regulatory network.

[0016] Preferably according to the present invention, the drug contains a pharmaceutically acceptable carrier.

[0017] The beneficial effects of the present invention are:

[0018] 1. The present invention clarifies the mechanism by which the intracellular LRP6 expression level and plasma membrane transport are regulated by the joint action of SDCCAG3 protein and VPS26 protein at the protein level, and provides a regulatory network for regulating the intracellular LRP6 expression level and plasma membrane transport, that is, SDCCAG3 protein and VPS26 protein jointly regulate the LRP6 expression level and plasma membrane transport in Hela cells, and the expression level of LRP6 is affected by SDCCAG3 protein and VPS26 protein, that is, when SDCCAG3 protein or VPS26 protein is knocked down in Hela cells, the expression level of LRP6 will also decrease; when SDCCAG3 protein or VPS26 protein is overexpressed in Hela cells, the expression level of LRP6 protein will increase.

[0019] 2. Based on the fact that the expression level of LRP6 is affected by SDCCAG3 and VPS26, the present invention further explored the mechanism and found that LRP6 is degraded by lysosomes in cells. Overexpression of both SDCCAG3 protein and VPS26 protein inhibits lysosomal degradation of LRP6, while knockdown of SDCCAG3 protein or VPS26 protein promotes lysosomal degradation of LRP6, which is of great significance for the treatment of osteoporosis in patients with hyperlipidemia and peri-implantitis. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 The images are of Hela cells observed under a microscope at 100 and 200 times magnification after 0, 24, and 48 hours of culture;

[0021] In the figure, 100×: 100 times the image; 200×: 200 times the image.

[0022] Figure 2 This is the Western blot result of Hela cells after SDCCAG3 was first knocked down by siRNA and then rescued by overexpressing SDCCAG3 using lentivirus.

[0023] In the figure, NC: negative control group; KD: knockdown group; rescue: rescue group

[0024] Figure 3 This is the Western blot result of Hela cells after lentivirus overexpression of SDCCAG3.

[0025] In the figure, NC: negative control group; OE: overexpression group.

[0026] Figure 4 Western blot results of Hela cells after knocking down VPS26 with siRNA targeting different sites and then rescuing VPS26 by overexpressing VPS26 using lentivirus;

[0027] In the figure, CG: blank control group; NC: negative control group; siRNA-509: knocking down VPS26 using siRNA-509; siRNA-604: knocking down VPS26 using siRNA-604; siRNA-771: knocking down VPS26 using siRNA-771; rescue: rescue group.

[0028] Figure 5 Immunofluorescence images of Hela cells after siRNA knockdown of SDCCAG3 and lentivirus overexpression of SDCCAG3;

[0029] In the figure, NC: negative control group; KD: knockdown group; OE: overexpression group; blue: DAPI, indicating cell nucleus; green: SDCCAG3; red: LRP6; 1000×: 1000 times microscope.

[0030] Figure 6 Immunofluorescence images of Hela cells after siRNA knockdown of VPS26 and lentivirus overexpression of VPS26.

[0031] In the figure, NC: negative control group; KD: knockdown group; OE: overexpression group; blue: DAPI, indicating cell nucleus; green: VPS26; red: LRP6; 1000×: 1000 times microscope.

[0032] Figure 7 This is the result of co-immunoprecipitation of LRP6 and SDCCAG3;

[0033] In the figure, Input: normal sample group; IgG: negative control group; IP: experimental group.

[0034] Figure 8 This is the result of immunoprecipitation of LRP6 and VPS26;

[0035] In the figure, Input: normal sample group; IgG: negative control group; IP: experimental group.

[0036] Fig. 9 The immunofluorescence co-localization results of SDCCAG3 and LRP6, VPS26 and LRP6, and VPS26 and SDCCAG3;

[0037] In Figures A to C, blue: DAPI, indicating cell nucleus, 1000×: 1000 times microscope; in Figure A, green: indicates SDCCAG3; red: indicates LRP6; in Figure B, green: indicates VPS26; red: indicates LRP6; in Figure C, green: indicates VPS26; red: indicates SDCCAG3.

[0038] Fig.10 The results of the changes in LRP6 expression levels in Hela cells after using clathrin inhibitors and caveolin inhibitors respectively;

[0039] In the figure, CG: blank control group; MDC: Hela cells added with the clathrin inhibitor MDC; Filipin III: Hela cells added with the caveolin inhibitor.

[0040] Fig.11 The effect of siRNA knockdown of SDCCAG3 on the colocalization of LRP6 and caveolin;

[0041] In the figure, NC: negative control group; KD: knockdown group; blue: DAPI, i.e., cell nucleus; green: Caveolin-1, i.e., caveolin; red: LRP6; 1000×: 1000 times microscope.

[0042] Fig.12 The effect of siRNA knockdown of SDCCAG3 on the colocalization of LRP6 and clathrin;

[0043] In the figure, NC: negative control group; KD: knockdown group; blue: DAPI, indicating the cell nucleus; green: Clathrin; red: LRP6; 1000×: 1000 times microscope.

[0044] Fig.13 Effects of different concentrations of lysosomal inhibitors and proteasome inhibitors on inhibiting LRP6 degradation

[0045] In the figure, CG: blank control group;

[0046] Bafilomycin A1 (200nm): lysosomal inhibitor Bafilomycin A1 was used at a concentration of 200nM;

[0047] Bafilomycin A1 (400nm): lysosomal inhibitor Bafilomycin A1 was used at a concentration of 400nM;

[0048] Bafilomycin A1 (800nm): lysosomal inhibitor Bafilomycin A1 was used at a concentration of 800nM;

[0049] MG-132: The proteasome inhibitor MG-132 was used at a concentration of 10 μM.

[0050] Fig.14 for the colocalization of LRP6 and lysosomes after the use of lysosomal inhibitors;

[0051] In the figure, CG: blank control group; EG: experimental group; blue: DAPI, indicating cell nucleus; green: LAMP1, a lysosomal marker; red: LRP6; 1000×: 1000 times microscope.

[0052] Fig.15 The effect of knocking down VPS26 on the co-localization of LRP6 and lysosomes when using the same concentration and time of lysosomal inhibitors;

[0053] In the figure, NC: negative control group; KD: knockdown group; blue: DAPI, indicating cell nucleus; green: LAMP1, a lysosomal marker; red: LRP6; 1000×: 1000 times microscope.

[0054] Fig.16 The effect of knocking down SDCCAG3 on the colocalization of LRP6 and lysosomes when using the same concentration and time of lysosomal inhibitors;

[0055] In the figure, NC: negative control group; KD: knockdown group; blue: DAPI, indicating cell nucleus; green: indicating lysosomal marker; red: indicating LRP6; 1000×: 1000 times microscope.

[0056] Fig.17 The effects of siRNA knockdown of VPS26 and lentiviral overexpression of SDCCAG3 after VPS26 knockdown on the expression level of LRP6;

[0057] In the figure, NC: negative control group; KD: siRNA knockdown of VPS26; rescue: lentivirus overexpression of SDCCAG3 after knockdown of VPS26. DETAILED DESCRIPTION

[0058] The present invention is further described below in conjunction with the examples, but the protection scope of the present invention is not limited thereto. The experimental operations involved in the examples are all carried out according to conventional operations unless otherwise specified; the drugs and reagents involved are all common commercially available products unless otherwise specified. Unless otherwise specified, the percentages in the examples are all mass percentages.

[0059] Example 1. Cultivation of Hela cells

[0060] Place high-glucose DMEM culture medium, PBS buffer, fetal bovine serum and trypsin in a 37°C constant temperature water bath for thorough thawing and preheating. After wiping the clean work surface with 75% alcohol cotton balls, turn on the UV switch for 30 minutes. Turn on the ventilation and lighting devices before use. Resuscitation, culture and subculture of cells should be carried out in a sterile environment in strict accordance with the laboratory's SOP procedures and regulations.

[0061] In the culture of Hela cells, a high-glucose DMEM medium containing 10% FBS was used, and after the operation, the cells were placed in a constant temperature incubator at 37°C and a carbon dioxide concentration of 5%. When the cells grew to about 80%, the old medium was discarded, and 5 ml of PBS buffer was used to gently shake and wash three times, and then 2 ml of 0.25% trypsin was added, and then placed in a 37°C incubator for digestion. After 2 minutes, it was taken out, and after observing under a microscope that the cells became round and no longer adhered to the wall, a complete medium was added with a pipette to terminate the digestion and the cells were repeatedly blown with a blowing pipette to make the cells fall off and disperse into single cells. Then, after centrifugation at a speed of 1000r / min for 5 minutes, complete medium was added to resuspend into a single cell suspension, and then the cells were passaged at a ratio of 1: (5-10), and then placed in a constant temperature incubator at 37°C and 5% CO2 for continued culture.

[0062] Under an inverted microscope, the subcultured Hela cells suspended in the freshly prepared culture medium are of uniform size, with regular round or oval shapes, scattered and not connected to each other. After 24 hours, it can be observed under an inverted microscope that most of the cells have attached to the wall and formed colonies in the cell culture dish. Among the cells that have attached to the wall, short spindle-shaped or triangular cells appear, and the number of round cells is still large. After 48 hours of culture, it can be seen that most of the cells in the cell culture dish have become long spindle-shaped cells, the content of round cells has further decreased, and the cells are closely connected, and the colonies have merged into sheets. For specific Hela cell morphology, please see Figure 1 .

[0063] Example 2: Hela cells transfected with siRNA to knock down SDCCAG3 / VPS26, and lentivirus infected to overexpress SDCCAG3 / VPS26

[0064] 1. Use small interfering RNA to knock down SDCCAG3 and VPS26 in Hela cells respectively. The specific steps are as follows:

[0065] 1) 24 hours before transfection, the Hela cells in good growth condition in Example 1 were digested with 0.25% trypsin and inoculated with 2-5×10 5 The cells were plated in a six-well plate and then cultured in a 5% carbon dioxide constant temperature incubator. During the plating process, the cells were completely digested and mixed to avoid cell accumulation and growth. Transfection was performed when the cell confluence was 30-50%.

[0066] 2) Use Opti-MEM to dilute siRNA so that the final concentration during transfection is 50 nM, and gently pipette 3 to 5 times to mix;

[0067] Wherein, the positive siRNA for knocking down VPS26A is siRNA-771, siRNA-509 or siRNA-604, and the sequence is as follows:

[0068] siRNA-771: 5'-CAACAGAAACAGAAACAAUTTAUUGUUUCUGUUUCUGUUGTT-3';

[0069] siRNA-509: 5'-GUGAGAAGACUGACAGAUUTTAAUCUGUCAGUCUUCACTT-3';

[0070] siRNA-604: 5'-GGGCAUUGAAGAUUGUCUATTUAGACAAUCUUCAAUGCCCTT-3'; the siRNA for knocking down SDCCAG3 is siRNA-385, the sequence is as follows

[0071] siRNA-385: 5'-CAGAAUUUAUGCAAAGGAATTUUCCUUUGCAUAAAUUCUGTT-3';

[0072] 3) Gently invert to mix the transfection reagent, dilute 5.0 μL of LipofectamineTM2000 with 250 μL of Opti-MEM, gently pipette 3 to 5 times to mix, and let stand at room temperature for 5 minutes (for a single well of a 6-well plate);

[0073] 4) Mix the transfection reagent and siRNA dilution solution, pipette gently 3 to 5 times to mix well, and let stand at room temperature for 20 minutes;

[0074] 5) The transfection complex was added to a 6-well plate at 500 μL / well and 1500 mL of incomplete culture medium was added. The cell plate was gently shaken back and forth to mix evenly. The cell plate was cultured in a constant temperature incubator at 37°C and 5% carbon dioxide. After 4 to 6 hours of transfection, the original blood-free culture medium was discarded and the complete culture medium was replaced to continue culturing the cells. After 48 hours of transfection, Hela cells with positive siRNA knockdown of SDCCAG3 and Hela cells with positive siRNA knockdown of VPS26 were obtained, and samples could be collected or other operations could be performed.

[0075] According to the same method, Hela cells were treated with negative siRNA as a negative control group to obtain Hela cells treated with negative siRNA control. The negative siRNA was a universal negative siRNA from General Biotechnology (Anhui) Co., Ltd.

[0076] 2. Use lentiviral infection to overexpress SDCCAG3 and VPS26 in Hela cells respectively. The specific steps are as follows:

[0077] 1) After the Hela cells in Example 1 reached a confluence of more than 80%, a cell counting plate was used to count 1.0×10 5 The cells were plated in 6-well cell culture plates, and then the most suitable concentration of purine was used to screen the stable transformation of cells, and cultured for 24 hours;

[0078] 2) Add complete cell culture medium with puromycin hydrochloride concentrations of 0, 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2, 1.5, 2.0, 2.5, and 3.0 μg / mL to a 6-well cell culture plate and replace the medium after 24 hours. Culture for a total of 72 hours in order to screen out the most appropriate concentration, even if the cells can be completely killed but the concentration is kept to a minimum to facilitate subsequent experiments;

[0079] 3) 1.0×10 5 When cells are completely attached and the cell confluence reaches 60%, virus can be added for infection.

[0080] 4) Before infection, discard the old culture medium, then add SDCCAG3 overexpression virus (SEQ ID NO.1) and VPS26 overexpression virus (SEQ ID NO.2) to the experimental group according to the optimal MOI (Multiply of Infection, multiplicity of infection = number of viruses / number of cells) value, use a pipette to blow the culture medium to disperse the virus evenly, then put it in a constant temperature incubator for further incubation, and replace the culture medium with new one on the second day, and put it in a constant temperature incubator for another incubation for 24 hours to obtain Hela cells overexpressing SDCCAG3 and VPS26, respectively, and then carry out subsequent corresponding experiments.

[0081] 3. After knocking down SDCCAG3 and VPS26 in Hela cells respectively according to method 1 in this example, SDCCAG3 and VPS26 in Hela cells were overexpressed according to method 2 in this example to obtain Hela cells in which SDCCAG3 and VPS26 were rescued respectively, i.e., the rescue group.

[0082] Example 3. Preparation and detection of protein immunoblot samples

[0083] Protein extraction was performed on Hela cells knocking down SDCCAG3 or VPS26 by positive siRNA (KD, knockdown group), Hela cells overexpressing SDCCAG3 or VPS26 (OE, overexpression group), Hela cells rescuing SDCCAG3 or VPS26 (rescue, rescue group), Hela cells treated with negative siRNA control (NC, negative control group) and Hela cells not treated at all (CG, blank control group) in Example 2, and then Western blot experiments were performed according to the prior art, specifically: (1) preparation of Western blot samples; (2) polyacrylamide gel electrophoresis; (3) membrane transfer; (4) blocking and antibody incubation; (5) development, observation and photography; internal reference was GAPDH. The obtained Western blot experimental results are shown in Figure 2. Figure 2 , 3 , 4, and 5.

[0084] Depend on Figure 2 It can be seen that after SDCCAG3 was knocked down, the expression level of LRP6 in Hela cells also showed a decrease, but if SDCCAG3 was overexpressed for rescue after knocking down SDCCAG3, the results showed that the expression level of LRP6 would be higher than when SDCCAG3 was only knocked down.

[0085] Depend on Figure 3 It can be seen that the expression level of LRP6 increased after overexpression of SDCCAG3 using lentivirus.

[0086] Depend on Figure 4 It can be seen that after VPS26 was knocked down, the expression level of LRP6 in Hela cells also showed a decrease, but if VPS26 was knocked down and then rescued using a lentivirus overexpressing VPS26, the expression level of LRP6 would be higher than when only VPS26 was knocked down.

[0087] Example 4: Immunofluorescence experiment

[0088] The Hela cells knocking down SDCCAG3 or VPS26 by positive siRNA (KD, knockdown group), Hela cells overexpressing SDCCAG3 or VPS26 (OE, overexpression group) and Hela cells treated with negative siRNA control (NC, negative control group) in Example 2 were fixed with 4% paraformaldehyde solution and then subjected to immunofluorescence experiment. The specific steps are as follows:

[0089] 1) Wash the confocal dish or slide with cells in room temperature PBS buffer three times, 3 minutes each time;

[0090] 2) Fix the cells with 4% paraformaldehyde solution at room temperature for 20 min, then gently wash with PBS buffer three times, 3 min each time;

[0091] 3) The cells were permeabilized with PBS buffer containing 0.2% Triton X-100 at room temperature for 5 min, and then gently washed with PBS buffer 3 times, 3 min each time.

[0092] 4) Goat serum blocking: absorb the remaining PBS buffer with absorbent paper, add PBS buffer containing 10% blocking goat serum, and block at room temperature for 30 minutes;

[0093] 5) Use absorbent paper to absorb the blocking solution, without washing, and add a sufficient amount of diluted primary antibody to each small dish or slide. If multiple antigens need to be stained, stain the antigen with less content first, then the antigen with rich content, and then place it in a humidified box and incubate overnight at 4°C;

[0094] 6) Add fluorescent secondary antibody: Wash with PBS buffer for 3 times, 5 min each time, dry the excess liquid on the slide with absorbent paper, and then add the diluted fluorescent secondary antibody dropwise in sequence, then place in a wet box, incubate at room temperature for 60 min away from light, and wash with PBS for 3 times, 5 min each time;

[0095] 7) Nuclear counterstaining: After adding DAPI, incubate in dark for 5 minutes to stain the cell nuclei of the specimen. After that, wash with PBS buffer 4 times for 5 minutes each time to wash away the excess DAPI.

[0096] 8) If it is a confocal dish: use absorbent paper to absorb the liquid on the slide in the confocal dish, add an appropriate amount of PBS buffer, and then directly place it under an ultra-high microscope for observation without adding anti-fluorescence quencher; If it is a slide: take out the slide from the cell culture plate, use absorbent paper to absorb the liquid on the slide, add anti-fluorescence quencher to a section of the side with the cell slide, gently pour the slide on the slide to avoid the generation of bubbles, let it stand at room temperature for 2 hours to let the slide settle naturally, then use nail polish to seal the edges and fix it, and then you can observe and collect images under a microscope and take pictures. The results are as follows: Figure 5 , 6 shown.

[0097] Depend on Figure 5 It can be seen that the brightness of green and red fluorescence in the KD group decreased compared with the NC group, while the number and brightness of green and red fluorescence in the OE group increased compared with the control group, indicating that when the expression level of SDCCAG3 in Hela cells decreased, the expression level of LRP6 also decreased; and when the expression level of SDCCAG3 increased, the expression level of LRP6 also increased.

[0098] Depend on Figure 6 It can be seen that the brightness of green and red fluorescence in the KD group was lower than that in the NC group, while that in the OE group was higher than that in the NC group, indicating that when the expression level of VPS26 in Hela cells decreased, the expression level of LRP6 would also decrease; and when the expression level of VPS26 increased, the expression level of LRP6 would also increase.

[0099] Example 5: Co-immunoprecipitation experiment

[0100] After extracting proteins from the untreated Hela cells cultured in Example 1, an immunoprecipitation experiment was performed, and the steps were as follows:

[0101] 1. Antigen sample preparation: Hela cells were inoculated in a 6-well cell culture plate. After culturing for 24 to 48 hours, the cell density reached more than 80%, and the culture medium was discarded. 5 After washing 10 cells twice with 150 μl of ice-cold 1× PBS buffer, the attached Hela cells were scraped off with a cell scraper and collected into a 1.5 mL EP tube. 5 Add 20-30 μl of binding buffer to each cell and add protease inhibitor PMSF (PMSF: binding buffer = 1:100), mix well and place on ice for 10 min, then centrifuge at 4°C and 14000g for 10 min to obtain the supernatant, place on ice for later use or store at -20°C for long-term storage;

[0102] 2. Magnetic bead pretreatment: Solarbio TMVortex the immunoprecipitation magnetic beads in the immunoprecipitation kit for 60 seconds to fully mix and evenly resuspend the magnetic beads, then take 25μl of the magnetic bead suspension and place it in a 1.5ml EP tube, and then add 200μl of binding buffer for washing and magnetic separation, that is, place the EP tube containing the magnetic bead suspension on a magnetic separator, so that the magnetic beads are magnetically adsorbed on the wall of the EP tube until the suspension becomes clear, then discard the supernatant and only retain the magnetic beads adsorbed on the tube wall, then remove the EP tube, repeat the above operation and wash once more, and after washing, add 200μl of binding buffer to resuspend the magnetic beads.

[0103] 3. Antigen binding reaction:

[0104] 1) Preparation of antibody working solution: Use Solarbio TM Dilute the antibody sample with the binding buffer in the immunoprecipitation kit to a final concentration of 5-50 μg / ml, and then place on ice for later use;

[0105] 2) Antibody adsorption: After the pre-treated magnetic bead suspension is magnetically separated again, the supernatant is discarded, and then 200 μl of antibody working solution is added, and then it is quickly resuspended and placed on a flip mixer at room temperature for flipping. After 15 minutes, magnetic separation is performed and the supernatant is collected and placed on ice for later use;

[0106] 3) Washing: Add 200 μl of binding buffer to the EP tube for washing, and use a pipette to gently blow and mix the magnetic bead-antibody complex evenly. After magnetic separation, discard the supernatant and repeat the above operation once.

[0107] 4. Antigen precipitation reaction

[0108] 1) Antigen adsorption: After adding 200 μl of the antigen sample prepared in step 3 to the EP tube, gently blow with a pipette to evenly mix and disperse the antigen and magnetic bead-antibody complex, and then place the EP tube on a flipping instrument at 4°C and gently flip the reaction overnight, so that the antigen and antibody can be fully mixed and combined;

[0109] 2) Washing and transfer: The magnetic beads-antibody-antigen complex that has completed antigen adsorption overnight is subjected to magnetic separation, and then the supernatant is collected and placed on ice for later use. Then 200 μl of the washing buffer in the kit is added to the EP tube for washing, and the magnetic beads-antibody-antigen complex is gently blown with a pipette to evenly disperse and wash, and then the supernatant is discarded after magnetic separation, and the above operation is repeated twice. After the washing, 200 μl of washing buffer is added, and after mixing, the magnetic beads-antibody-antigen complex suspension is transferred to a new 1.5 ml EP tube to avoid eluting the original non-specific adsorbed protein on the old tube wall, and then magnetic separation is performed and the supernatant is discarded.

[0110] 5. Antigen elution: In order to conduct SDS-PAGE detection later, the denaturing elution method is used, that is, 25 μl of 1×SDS-PAGE Loading Buffer is added to the new EP tube after the above treatment, mixed evenly, and placed at 95℃ for 5 minutes, and then magnetic separation is performed and the supernatant is collected for SDS-PAGE detection. The results are as follows: Figure 7 , 8 shown.

[0111] Depend on Figure 7 , 8 It can be seen that there are protein bands in the Input group, and there is a protein blot in the IP group, indicating that LRP6 interacts with SDCCAG3 and VPS26 proteins respectively. The treatment of Hela cells is not grouped, that is, ordinary Hela cells. The Input group refers to the group in which the total protein is extracted from the cells for the experiment, that is, the positive control group; the IgG group is the extracted protein that is subjected to the following treatment and then subjected to a precipitation experiment using non-related IgG to exclude the false positive phenomenon caused by the nonspecific binding of the experimental group protein and IgG, that is, the negative control group; IP: The experimental group is the group in which the extracted protein is subjected to the following treatment and then subjected to the experiment.

[0112] Example 6: Co-localization between any two of LRP6, SDCCAG3 and VPS26

[0113] The Hela cells cultured in Example 1 were divided into three groups (groups A, B and C), and 1.0×10 5 Hela cells were placed in a constant temperature incubator and incubated overnight. After the Hela cells were observed to be basically attached to the wall under an inverted microscope, immunofluorescence co-localization experiments were performed after treatment with SDCCAG3 / LRP6 antibody (group A), VPS26 / LRP6 antibody (group B) and SDCCAG3 / VPS26 antibody (group C). The results are shown in Figure 2. Fig. 9 The antibodies were purchased from Santa Clara Company.

[0114] Depend on Fig. 9 It can be seen that SDCCAG3 is distributed in both the cytoplasm and the nucleus, while LRP6 and VPS26 are mainly present in the cytoplasm. There are fluorescence co-localization points between SDCCAG3 and LRP6; there are fluorescence co-localization points between VPS26 and LRP6; there are also fluorescence co-localization points between SDCCAG3 and VPS26; that is, there is co-localization between any two of SDCCAG3, LRP6 and VPS26. Combining the IP results, it can be concluded that LRP6, SDCCAG3 and VPS26 can bind to each other.

[0115] Example 7: Verification of LRP6 endocytic pathway

[0116] 1. Use of clathrin inhibitors

[0117] 1) Preparation of MDC stock solution: Add 2.981 mL of 100 mg / mL DMSO solution to 5 mg of MDC powder to prepare the powder into a 5 mM stock solution, which needs to be dissolved with ultrasound assistance, and then stored in a -80°C refrigerator;

[0118] 2) Hela cells were plated in 6-well plates, with 1.0×10 5 Hela cells were plated, and when the cell confluence reached 60-80%, the MDC stock solution was diluted to a concentration of 50 μM using complete culture medium, 2 mL of the dilution was added to each well of a 6-well plate, and then the plate was placed in a 37°C constant temperature incubator and incubated for 30 min to obtain Hela cells added with the clathrin inhibitor MDC (MDC group).

[0119] 2. Use of caveolin inhibitors

[0120] HeLa cells were plated in 6-well plates at 1.0 × 10 5 Hela cells were plated, and when the cell confluence reached 60-80%, the stock solution of Filipin III was diluted to a concentration of 5 μg / mL using complete culture medium, 2 mL of the dilution was added to each well of a 6-well plate, and then the plate was placed in a constant temperature incubator at 37°C and incubated for 30 min to obtain Hela cells added with the caveolin inhibitor Filipin III (Filipin III group).

[0121] 3. Extraction of membrane proteins

[0122] Membrane proteins were extracted from the MDC group, Filipin III group, and Hela cells without inhibitors (CG group), and then Western blot experiments were performed. The results are shown in Fig.10 As shown, the specific method is as follows:

[0123] 1) Collect Hela cells that grow on the wall. After centrifugation, there should be at least 1×10 7 The Hela cells were then washed with pre-cooled PBS solution and centrifuged at 3000 rpm for 5 min. The above operation was repeated three times.

[0124] 2) Add 1 mL of the extraction buffer in the kit to the precipitated Hela cells after centrifugation (1 μL of protease inhibitor and 1 μL of DTT were added to 1 mL of the extraction buffer in advance), and then use ultrasound to break the cells on ice;

[0125] 3) Place the disrupted Hela cell solution into a 1.5 mL pre-cooled centrifuge tube and let it stand for 10 min. Take it out 3 to 4 times and shake the centrifuge tube vigorously. Centrifuge it at 14,000 rpm for 10 min at 4°C. Transfer the supernatant to a new 1.5 mL tube.

[0126] 4) The obtained supernatant was heated in a 37°C water bath for 10 min, returned to room temperature, and then centrifuged at 14,000 rpm for 10 min. The upper layer was discarded, and the lower precipitate contained membrane proteins;

[0127] 5) Add 500 μL of pre-cooled sterile water to the lower solution, let it stand at 4°C for 5 minutes, then heat it in a 37°C water bath for 10 minutes, and then centrifuge it at 14,000 rpm for 10 minutes at 4°C. Discard the upper layer and repeat the above operation twice. The final lower solution is the extract of membrane protein, which should be stored at -80°C.

[0128] Depend on Fig.10 It can be seen that the expression level of LRP6 on the cell membrane increased significantly after using the caveolin pathway inhibitor Filipin III, indicating that LRP6 mainly depends on the caveolin pathway for endocytosis.

[0129] Example 8: Identification of the effect of SDCCAG3 on the LRP6 endocytic pathway

[0130] Hela cells in which SDCCAG3 or VPS26 was knocked down by positive siRNA in Example 2 (KD, knockdown group) and Hela cells treated with negative siRNA control (NC, negative control group) were taken, and immunofluorescence co-localization of LRP6 / clathrin and LRP6 / caveolin was performed according to the method described in Example 4. The results are shown in FIG. Fig.11 , 12 shown.

[0131] Depend on Fig.11 , 12 It can be seen that whether SDCCAG3 is knocked down or not, the co-localization of LRP6 with clathrin and caveolin-1 is not affected, indicating that knocking down SDCCAG3 does not affect the endocytic pathway of LRP6.

[0132] Example 9: Identification of lysosomal degradation pathways

[0133] 1. Lysosome inhibition experiment

[0134] 1) Preparation of Bafilomycin A1 stock solution: Add 1.6056 mL of 100 mg / mL DMSO solution to 10 mg of Bafilomycin A1 powder to prepare a 10 mM stock solution, and then store the solution in aliquots at -80°C.

[0135] 2) Hela cells were plated in 6-well plates, with 1.0×10 5 Hela cells were plated, and when the cell confluence reached 60-80%, the Bafilomycin A1 stock solution was diluted to different concentrations of 200 nM, 400 nM, and 800 nM using complete culture medium, 2 mL of the dilution was added to each well of a 6-well plate, and then the plate was placed in a constant temperature incubator at 37°C and incubated for 4 hours to obtain 3 groups of Hela cells after the addition of the lysosomal inhibitor Bafilomycin A1, namely, the Bafilomycin A1 (200 nm) group, the Bafilomycin A1 (400 nm) group, and the Bafilomycin A1 (800 nm) group.

[0136] 2. Proteasome inhibition experiment

[0137] 1) Preparation of MG-132 stock solution: Add 1.0513 mL of 100 mg / mL DMSO solution to 5 mg of MG-132 powder to prepare a 10 mM stock solution, and then store the solution in aliquots at -80°C.

[0138] 2) Hela cells were plated in 6-well plates, with 1.0×10 5 Hela cells were added, and when the cell confluence reached 60-80%, the MG-132 stock solution was diluted to a concentration of 10 μM using complete culture medium, 2 mL of the dilution was added to each well of a 6-well plate, and then the plate was placed in a constant temperature incubator at 37°C and incubated for 1 hour to obtain Hela cells after the proteasome inhibitor MG-132A1 was added, which was the MG-132A1 group.

[0139] 3. The membrane proteins of Bafilomycin A1 (200nm), Bafilomycin A1 (400nm), Bafilomycin A1 (800nm), MG-132A1 and Hela cells without inhibitors (CG group) were extracted and then subjected to Western blot. The results are shown in Figure 3. Fig.13 shown.

[0140] Depend on Fig.13 It can be seen that only the use of lysosomal inhibitors can increase the expression of LRP6, indicating that LRP6 is degraded through lysosomes.

[0141] 4. Hela cells were plated in 6-well plates, 1.0×10 5 Hela cells were plated, and when the cell confluence reached 60-80%, the stock solution of Bafilomycin A1 was diluted to a concentration of 200 nM using complete culture medium, 2 mL of the dilution was added to each well of a 6-well plate, and then placed in a constant temperature incubator at 37°C for further incubation for 4 hours to obtain Hela cells after the addition of the lysosomal inhibitor Bafilomycin A1, which was used as the experimental group (EG).

[0142] Then, immunofluorescence experiments were performed on the experimental group (EG) and Hela cells without inhibitor addition (CG group) according to the method described in Example 4. The results are as follows: Fig.14 shown.

[0143] Depend on Fig.14 It can be seen that when lysosomal inhibitors are used, the fluorescence brightness of LRP6 increases, and the co-localization with lysosomes increases, indicating that LRP6 is mainly degraded through lysosomes.

[0144] Example 10: Effects of SDCCAG3 and VPS26 on LRP6 transport endpoints

[0145] Hela cells in which SDCCAG3 or VPS26 was knocked down by positive siRNA in Example 2 (KD, knockdown group) and Hela cells treated with negative siRNA control (NC, negative control group) were taken, and 200 nM Bafilomycin A1 was added respectively according to the method described in Example 9, and the cells were incubated in a constant temperature incubator at 37° C. for 4 hours.

[0146] Then, immunofluorescence experiments were performed on Hela cells (NC, negative control group) treated with the same concentration and time of lysosomal inhibitors and the knockdown group (KD) and the negative siRNA control group (NC) according to the method described in Example 4. The results are as follows: Fig.15 , 16 shown.

[0147] Depend on Fig.15 It can be seen that when lysosomal function is inhibited, LRP6 accumulates more in the KD group than in the NC group, which indicates that the function of SDCCAG3 and VPS26 is to prevent LRP6 from transporting to lysosomes. In the absence of SDCCAG3 or VPS26, LRP6 will accumulate more in lysosomes. When lysosomal function is normal, LRP6 will decrease due to the decrease in SDCCAG3 expression level. That is, knockdown of SDCCAG3 protein or VPS26 protein will promote lysosomal degradation of LRP6.

[0148] Example 11: The effect of SDCCAG3 on LRP6 plasma membrane translocation requires the co-action of VPS26

[0149] Lentivirus overexpressing SDCCAG3 was added to the Hela cells in which VPS26 was knocked down by positive siRNA in Example 2 (KD, knockdown group), to obtain Hela cells in which VPS26 was knocked down and SDCCAG3 was overexpressed (rescue, rescue group), and proteins of the cells, Hela cells in which VPS26 was knocked down by positive siRNA in Example 2 (KD, knockdown group) and untreated Hela cells (NC, negative control group) were extracted, and then Western blot experiments were performed. The results are shown in FIG. Fig.17 shown.

[0150] Depend on Fig.17 It can be seen that the expression level of LRP6 decreased after knocking down VPS26, but after overexpressing SDCCAG3, the expression level of LRP6 did not increase with the increase of SDCCAG3 expression level, indicating that SDCCAG3 needs to prevent LRP6 from being degraded by lysosomes through VPS26. That is, overexpression of both SDCCAG3 protein and VPS26 protein can inhibit lysosomal degradation of LRP6.

Claims

1. A regulatory network for regulating intracellular LRP6 expression level and plasma membrane transport, characterized in that: The regulatory network is the SDCCAG3 protein-VPS26 protein regulatory network; The Gene ID of the SDCCAG3 protein is 10807; the Gene ID of the VPS26 protein is 9559.

2. Use of the regulatory network according to claim 1 in the preparation of drugs for treating osteoporosis and peri-implantitis, characterized in that: The application is the use of the regulatory factors of the above regulatory network in the preparation of drugs for treating osteoporosis and peri-implantitis.

3. The use according to claim 2, characterized in that The regulatory factors of the regulatory network include, but are not limited to, nucleic acid molecules, carbohydrates, lipids, polypeptides, proteins or lentiviruses.

4. The use according to claim 2, characterized in that The drug regulates the expression level of LRP6 through SDCCAG3 and / or VPS26 proteins. When SDCCAG3 and / or VPS26 are knocked down, the expression of LRP6 decreases, and when SDCCAG3 and / or VPS26 are overexpressed, the expression of LRP6 increases.

5. The use according to claim 2, wherein the osteoporosis is osteoporosis caused by or accompanied by hyperlipidemia; and the peri-implantitis is peri-implantitis caused by or accompanied by hyperlipidemia.

6. The use according to claim 2, wherein the drug contains an effective dose of the regulatory factor of the above-mentioned regulatory network.

7. The use according to claim 2, wherein the medicine contains a pharmaceutically acceptable carrier.